Linda Fogelstrand

Dr. Linda Fogelstrand

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2026 in Blood
Verified
Journal Article
Closed access
C Michel ZwaanC Michel Zwaan
C Michel Zwaan
STSarah Tasian
Sarah Tasian
RARichard Aplenc
Richard Aplenc
LBLisa E. Brodersen
Lisa E. Brodersen
BBBarbara Buldini
Barbara Buldini
TCTodd M Cooper
Todd M Cooper
The European LeukemiaNet has periodically issued guidelines for the diagnosis and management of acute myeloid leukemia (AML) in adults. These consensus recommendations, most recently updated in 2022, incorporate recent advances in genomic testing, disease detection methods, target identification, and response assessment. Although similarities exist between AML in children and adults, pediatric AML is frequently characterized by unique cytogenetic and molecular features, which require distinct genetic and immunophenotypic diagnostics, therapeutic approaches, response assessment criteria, and supportive care strategies. To address these specific needs, an international panel of pediatric hematologist-oncologists, biologists, geneticists, and laboratory medicine scientists convened to develop recommendations for the diagnosis and management of AML in children, adolescents, and young adults (hereafter termed pediatric AML) that are discussed in this special report.

12 July 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ACAlessandro Camponeschi
Alessandro Camponeschi
KKKathrin Kläsener
Kathrin Kläsener
TSTimothy Sundell
Timothy Sundell
CLChristina Lundqvist
Christina Lundqvist
PMPaul T. Manna
Paul T. Manna
IMInga-Lill Mårtensson
Inga-Lill Mårtensson
CD38 is a multifunctional protein expressed on the surface of B cells in healthy individuals but also in B cell malignancies. Previous studies have suggested a connection between CD38 and components of the IgM class B cell antigen receptor (IgM-BCR) and its coreceptor complex. Here, we provide evidence that CD38 is closely associated with CD19 in resting B cells and with the IgM-BCR upon engagement. We show that targeting CD38 with an antibody, or removing this molecule with CRISPR/Cas9, inhibits the association of CD19 with the IgM-BCR, impairing BCR signaling in normal and malignant B cells. Together, our data suggest that CD38 is a new member of the BCR coreceptor complex, where it exerts a modulatory effect on B cell activation upon antigen recognition by regulating CD19. Our study also reveals a new mechanism where α-CD38 antibodies could be a valuable option in therapeutic approaches to B cell malignancies driven by aberrant BCR signaling.

8 September 2013 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
KJK Jennbacken
K Jennbacken
SSS Ståhlman
S Ståhlman
LGL Grahnemo
L Grahnemo
OWO Wiklund
O Wiklund
LFLinda Fogelstrand
Linda Fogelstrand
Summary: B-1 lymphocytes produce natural immunoglobulin (Ig)M, among which a large proportion is directed against apoptotic cells and altered self-antigens, such as modified low-density lipoprotein (LDL). Thereby, natural IgM maintains homeostasis in the body and is also protective against atherosclerosis. Diabetic patients have an increased risk of developing certain infections as well as atherosclerosis compared with healthy subjects, but the underlying reason is not known. The aim of this study was to investigate whether diabetes and insulin resistance affects B-1 lymphocytes and their production of natural IgM. We found that diabetic db/db mice had lower levels of peritoneal B-1a cells in the steady state-condition compared to controls. Also, activation of B-1 cells with the Toll-like receptor (TLR)-4 agonist Kdo2-Lipid A or immunization against Streptococcus pneumoniae led to a blunted IgM response in the diabetic db/db mice. In-vitro experiments with isolated B-1 cells showed that high concentrations of glucose, but not insulin or leptin, caused a reduced secretion of total IgM and copper-oxidized (CuOx)-LDL- and malondialdehyde (MDA)-LDL-specific IgM from B-1 cells in addition to a decreased differentiation into antibody-producing cells, proliferation arrest and increased apoptosis. These results suggest that metabolic regulation of B-1 cells is of importance for the understanding of the role of this cell type in life-style-related conditions.

8 June 2016 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
EMErik B.R. Malmberg
Erik B.R. Malmberg
SSSara Ståhlman
Sara Ståhlman
ARAnna Rehammar
Anna Rehammar
TSTore Samuelsson
Tore Samuelsson
SASofie J. Alm
Sofie J. Alm
LFLinda Fogelstrand
Linda Fogelstrand

16 March 2020 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
KJKristian Løvvik Juul‐Dam
Kristian Løvvik Juul‐Dam
HOHans Beier Ommen
Hans Beier Ommen
CNCharlotte Guldborg Nyvold
Charlotte Guldborg Nyvold
CWChristiane Walter
Christiane Walter
HVHelen Vålerhaugen
Helen Vålerhaugen
HHHenrik Hasle
Henrik Hasle
Summary: Serial assessments of measurable (or minimal) residual disease (MRD) by qPCR may identify nascent relapse in children with acute myeloid leukaemia (AML) and enable pre‐emptive therapy. We investigated the kinetics and prognostic impact of recurrent fusion transcripts (RUNX1‐RUNX1T1, CBFB‐MYH11, KMT2A‐MLLT3 or KMT2A‐ELL) in 774 post‐induction samples from bone marrow (BM, 347) and peripheral blood (PB, 427) from 75 children with AML. BM MRD persistence during consolidation did not increase the risk of relapse, and MRD at therapy completion did not correlate to outcome (HR = 0·64/MRD log reduction (CI: 0·32–1·26), P = 0·19). In contrast, 8/8 patients with detectable MRD in PB after first consolidation relapsed. Persistence (n = 4) and shifting from negative to positive (n = 10) in PB during follow‐up predicted relapse in 14/14 patients. All 253 PB samples collected during follow‐up from 36 patients in continuous complete remission were MRD negative. In core‐binding factor AML, persistent low‐level MRD positivity in BM during follow‐up was frequent but an increment to above 5 × 10−4 heralded subsequent haematological relapse in 12/12 patients. We demonstrate that MRD monitoring in PB after induction therapy is highly informative and propose an MRD increment above 5 × 10−4 in PB and BM as a definition of molecular relapse since it always leads to haematological relapse.

30 May 2021 in International Journal of Laboratory Hematology
Verified
Journal Article
Open access
PDF file
LPLouise Pettersson
Louise Pettersson
SASofie Johansson Alm
Sofie Johansson Alm
AAAlvar Almstedt
Alvar Almstedt
YCYilun Chen
Yilun Chen
GOGustav Orrsjö
Gustav Orrsjö
MEMats Ehinger
Mats Ehinger
Introduction: Reverse transcriptase quantitative PCR (RT‐qPCR) is considered the method of choice for measurable residual disease (MRD) assessment in NPM1‐mutated acute myeloid leukemia (AML). MRD can also be determined with DNA‐based methods offering certain advantages. We here compared the DNA‐based methods quantitative PCR (qPCR), droplet digital PCR (ddPCR), and targeted deep sequencing (deep seq) with RT‐qPCR.Methods: Of 110 follow‐up samples from 30 patients with NPM1‐mutated AML were analyzed by qPCR, ddPCR, deep seq, and RT‐qPCR. To select DNA MRD cutoffs for bone marrow, we performed receiver operating characteristic analyses for each DNA method using prognostically relevant RT‐qPCR cutoffs.Results: The DNA‐based methods showed strong intermethod correlation, but were less sensitive than RT‐qPCR. A bone marrow cutoff at 0.1% leukemic DNA for qPCR or 0.05% variant allele frequency for ddPCR and deep seq offered optimal sensitivity and specificity with respect to 3 log10 reduction of NPM1 transcripts and/or 2% mutant NPM1/ABL. With these cutoffs, MRD results agreed in 95% (191/201) of the analyses. Although more sensitive, RT‐qPCR failed to detect leukemic signals in 10% of samples with detectable leukemic DNA.Conclusion: DNA‐based MRD techniques may complement RT‐qPCR for assessment of residual leukemia. DNA‐based methods offer high positive and negative predictive values with respect to residual leukemic NPM1 transcripts at levels of importance for response to treatment. However, moving to DNA‐based MRD methods will miss a proportion of patients with residual leukemic RNA, but on the other hand some MRD samples with detectable leukemic DNA can be devoid of measurable leukemic RNA.